As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

an intranasal formulation of glucagon, for the treatment of severe hypoglycemia. Baqsimi is dispensed into a nostril via a pre-filled nasal applicator. Each dose delivers 3 mg of glucagon in ...

The 39-year-old, best known for playing Buffy the Vampire Slayer's younger sister Dawn Summers was found dead at her home in New York in February.

“Often, when we are with a patient who is not meeting treatment goals, we need to decide whether to increase a current medication to maximum dose or ... generation glucagon-like peptide 1 ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

Potential side effects include gastrointestinal issues, pancreatitis, hypoglycemia ... company said it has introduced Mounjaro in a single-dose vial presentation following the marketing ...

The growing prevalence of diabetes, primarily due to obesity, aging populations, and sedentary lifestyles, is a key factor ...

Amylyx Pharmaceuticals, Inc.’s AMLX share price has surged by 13.17%, which has investors questioning if this is right time to sell.

Both of these drugs belong to a class of medications called glucagon-like peptide-1 receptor ... needle to the pen each time you administer a dose. You’ll turn the dose selector on the pen ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...